Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Undifferentiated Sarcoma: early-phase trial registry
2 of 3 indexed Undifferentiated Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Undifferentiated Sarcoma: 3 US clinical trials tracked, 2 recruiting.
Undifferentiated Sarcoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition undifferentiated-sarcoma
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Undifferentiated Sarcoma lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Undifferentiated Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Undifferentiated Sarcoma is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Lurbinectedin in FET-Fused Tumors
Children's Hospital of Philadelphia
NCT05918640
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
NCT04995003
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03241745
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Undifferentiated Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Undifferentiated Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Undifferentiated Sarcoma page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Undifferentiated Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Undifferentiated Sarcoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Undifferentiated Sarcoma condition card totals 3 registered trials; most-linked intervention Pembrolizumab Injectable Product; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.